UEG Journal

Key takeaway messages

1. Salivary molecular signatures may offer a non-invasive way to detect gastric cancer, with SLC5A5 emerging as a promising biomarker.

2. Real-world registry data show upadacitinib to be effective and generally safe in patients with Crohn’s disease, supporting its use beyond clinical trials.

3. Endoscopic ultrasound-guided gastroenterostomy demonstrates better cost-effectiveness compared with surgical gastrojejunostomy in a randomized health-economic analysis.